Ask AI
S. 139Became Law

Ensuring Access to Clinical Trials Act of 2015

This measure has not been amended since it was introduced. The expanded summary of the Senate-passed version is repeated here.)

Ensuring Access to Clinical Trials Act of 2015

(Sec. 2) This bill amends the Improving Access to Clinical Trials Act of 2009 to repeal the sunset of, and so extend indefinitely, the exclusion from resources under titles XVI (Supplemental Security Income) and XIX (Medicaid) of the Social Security Act, for eligibility purposes, of compensation in the amount of the first $2,000 per year received by individuals who participate in clinical trials for rare diseases or conditions.

Became Public Law No: 114-63.

Sen. Wyden, Ron [D-OR](D-OR)Sponsor
15 cosponsors10 D5 R
15cosponsors3committees25actions1related bills3subjects
  • Enrolled Bill
  • Referred in HouseJul 20, 2015
  • Engrossed in SenateJul 16, 2015
  • Introduced in SenateJan 8, 2015
  • Public LawOct 8, 2015
  1. President

    Became Public Law No: 114-63.

  2. BecameLaw36000

    Became Public Law No: 114-63.

  3. President

    Signed by President.

  4. BecameLaw36000

    Signed by President.

  5. Floor

    Presented to President.

  6. President28000

    Presented to President.

  7. FloorH38310

    Motion to reconsider laid on the table Agreed to without objection.

  8. FloorH37300

    On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H6276)

  9. Floor8000

    Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote.(text: CR H6276)

  10. FloorH8D000

    DEBATE - The House proceeded with forty minutes of debate on S. 139.

  11. FloorH30000

    Considered under suspension of the rules. (consideration: CR H6276-6279)

  12. FloorH30300

    Mr. Ryan (WI) moved to suspend the rules and pass the bill.

  13. Committee

    Referred to the Subcommittee on Health.

  14. Committee

    Referred to the Subcommittee on Health.

  15. IntroReferralH11100

    Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  16. IntroReferralH11100

    Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  17. IntroReferralH11100-A

    Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  18. FloorH14000

    Received in the House.

  19. Floor

    Message on Senate action sent to the House.

  20. Floor

    Passed Senate without amendment by Unanimous Consent. (consideration: CR S5175; text as passed Senate: CR S5175)

  21. Floor17000

    Passed/agreed to in Senate: Passed Senate without amendment by Unanimous Consent.(consideration: CR S5175; text as passed Senate: CR S5175)

  22. Discharge

    Senate Committee on Finance discharged by Unanimous Consent.

  23. Committee14500

    Senate Committee on Finance discharged by Unanimous Consent.

  24. IntroReferral

    Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S105; text of measure as introduced: CR S105)

  25. IntroReferral10000

    Introduced in Senate

Oct 7, 201549

This measure has not been amended since it was introduced. The expanded summary of the Senate-passed version is repeated here.)

Ensuring Access to Clinical Trials Act of 2015

(Sec. 2) This bill amends the Improving Access to Clinical Trials Act of 2009 to repeal the sunset of, and so extend indefinitely, the exclusion from resources under titles XVI (Supplemental Security Income) and XIX (Medicaid) of the Social Security Act, for eligibility purposes, of compensation in the amount of the first $2,000 per year received by individuals who participate in clinical trials for rare diseases or conditions.

Sep 28, 201581

(This measure has not been amended since it was introduced. The expanded summary of the Senate-passed version is repeated here.)

Ensuring Access to Clinical Trials Act of 2015

(Sec. 2) This bill amends the Improving Access to Clinical Trials Act of 2009 to repeal the sunset of, and so extend indefinitely, the exclusion from resources under titles XVI (Supplemental Security Income) and XIX (Medicaid) of the Social Security Act, for eligibility purposes, of compensation in the amount of the first $2,000 per year received by individuals who participate in clinical trials for rare diseases or conditions.

Jul 16, 201582

(This measure has not been amended since it was introduced. The summary has been expanded because action occurred on the measure.)

Ensuring Access to Clinical Trials Act of 2015

(Sec. 2) This bill amends the Improving Access to Clinical Trials Act of 2009 to repeal the sunset of, and so extend indefinitely, the exclusion from resources under titles XVI (Supplemental Security Income) and XIX (Medicaid) of the Social Security Act, for eligibility purposes, of compensation in the amount of the first $2,000 per year received by individuals who participate in clinical trials for rare diseases or conditions.

Jan 8, 2015

Ensuring Access to Clinical Trials Act of 2015

This bill amends the Improving Access to Clinical Trials Act of 2009 to repeal the sunset of, and so extend indefinitely, the exclusion from resources under titles XVI (Supplemental Security Income) and XIX (Medicaid) of the Social Security Act, for eligibility purposes, of compensation in the amount of the first $2,000 per year received by individuals who participate in clinical trials for rare diseases or conditions.

Ensuring Access to Clinical Trials Act of 2015 — Informed